Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network

Open access
Ying, Haoqiang, Elpek, Kutlu G., Vinjamoori, Anant, Zimmerman, Stephanie M., Chu, Gerald C., Yan, Haiyan, Fletcher-Sananikone, Eliot, Zhang, Hailei, Liu, Yingchun, Wang, Wei, Ren, Xiaojia, Zheng, Hongwu, Kimmelman, Alec C., Paik, Ji-hye, Lim, Carol, Perry, Samuel R., Jiang, Shan, Malinn, Brian, Protopopov, Alexei, Colla, Simona, Xiao, Yonghong, Hezel, Aram F., Bardeesy, Nabeel, Turley, Shannon J., Wang, Y. Alan, Chin, Lynda, Thayer, Sarah P., DePinho, Ronald A.·2011·Cancer Discovery

Abstract

Initiation of pancreatic ductal adenocarcinoma (PDAC) is driven by oncogenic KRAS mutation, and disease progression is associated with frequent loss of tumor suppressors. In this study, human PDAC genome analyses revealed frequent deletion of the PTEN gene as well as loss of expression in primary tumor specimens. A potential role for PTEN as a haploinsufficient tumor suppressor is further supported by mouse genetic studies. The mouse PDAC driven by oncogenic Kras mutation and Pten deficiency also sustains spontaneous extinction of Ink4a expression and shows prometastatic capacity. Unbiased transcriptomic analyses established that combined oncogenic Kras and Pten loss promotes marked NF-κB activation and its cytokine network, with accompanying robust stromal activation and immune cell infiltration with known tumor-promoting properties. Thus, PTEN/phosphoinositide 3-kinase (PI3K) pathway alteration is a common event in PDAC development and functions in part to strongly activate the NF-κB network, which may serve to shape the PDAC tumor microenvironment. Significance: Detailed molecular genetics studies established that PTEN operates as a haploinsufficient tumor suppressor to promote metastatic PDAC development. The strong activation of the NF-κB–cytokine program in Pten-deficient tumors provides additional avenues for targeted therapies in tumors with altered PI3K regulation. Cancer Discovery; 1(2); 158–69. ©2011 AACR. Read the Commentary on this article by Chiao and Ling, p. 103 This article is highlighted in the In This Issue feature, p. 91

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-11-0031

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 223

Metadata

Authors
Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., Ren, X., Zheng, H., Kimmelman, A. C., Paik, J.-H., Lim, C., Perry, S. R., Jiang, S., Malinn, B., Protopopov, A., Colla, S., Xiao, Y., Hezel, A. F., Bardeesy, N., Turley, S. J., Wang, Y. A., Chin, L., Thayer, S. P., & DePinho, R. A.
Venue
Cancer Discovery
Published
2011-07-01
Volume
1
Issue
2
Pages
158-169
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2138039462
Cited by
223
References
8
FWCI
6.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network. https://app.cochat.ai/papers/10.1158/2159-8290.cd-11-0031
The paper
Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., Ren, X., Zheng, H., Kimmelman, A. C., Paik, J.-H., Lim, C., Perry, S. R., Jiang, S., Malinn, B., Protopopov, A., . . . DePinho, R. A. (2011). PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-11-0031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.